Hospice Enrollment HALTED – Fraud Fears Explode

Medicare enrollment form with glasses and pen.

The Trump administration has frozen new Medicare enrollments for hospice and home health providers, a sweeping regulatory action that signals a dramatic shift away from Biden-era oversight and raises urgent questions about patient safety in an industry plagued by fraud.

Quick Take

Trump administration freezes new Medicare enrollments for hospice and home health agencies, expanding regulatory pause beyond the suspended Hospice Special Focus Program
Freeze prevents approximately 33,000 Medicare-certified hospices from accepting new patients, creating potential access disruptions for vulnerable elderly beneficiaries
Move reflects broader deregulation agenda but leaves 20% of hospices with documented serious safety deficiencies operating without enhanced oversight
Industry celebrates reprieve from enforcement while patient advocates warn of fraud and quality risks in $25 billion-plus Medicare hospice sector

Regulatory Freeze Expands Beyond Previous Suspension

Building on the suspension of the Hospice Special Focus Program, the Trump administration has now implemented a comprehensive freeze on new Medicare enrollments for hospice and home health providers. This expanded action prevents new agencies from joining the Medicare program entirely, effectively halting industry growth and creating barriers for beneficiaries seeking care from providers outside the existing network. The freeze represents the most restrictive hospice policy action since the SFP suspension, signaling intensified regulatory intervention despite the administration’s stated deregulation philosophy.

Industry Growth Halted Amid Fraud Concerns

The hospice sector has experienced substantial growth, with Medicare expenditures exceeding $25 billion annually. This expansion coincided with documented quality and fraud concerns, including investigations into fraudulent billing practices, enrollment of non-terminally ill patients, and unnecessary service provision. Office of Inspector General research found approximately 20% of hospice agencies operating with serious safety deficiencies. The enrollment freeze effectively prevents new providers—potentially including high-quality operators—from entering the market, consolidating existing provider networks while leaving documented problem agencies operating under standard oversight mechanisms.

Access Implications for Medicare Beneficiaries

Approximately 70 million Medicare enrollees, with 1.5 to 2 million annually utilizing hospice services, face potential access constraints from the enrollment freeze. Rural areas may experience disproportionate impact if existing providers cannot expand capacity or if new rural-focused agencies cannot enter the market. Low-income beneficiaries, potentially more vulnerable to fraudulent billing and quality variations, lack alternative enrollment pathways. The freeze creates a paradoxical regulatory environment: preventing new providers from entering while simultaneously suspending enhanced oversight of existing agencies with documented deficiencies.

Regulatory Philosophy Shift and Industry Response

The freeze reflects the Trump administration’s stated commitment to regulatory relief and reduced enforcement burden on healthcare providers. State hospice associations and the National Alliance for Care at Home have framed the suspension and freeze as necessary corrections to Biden-era overreach. However, the comprehensive enrollment freeze represents a more interventionist regulatory approach than simple deregulation, suggesting the administration is using regulatory authority to reshape industry composition rather than simply reducing oversight burden on existing providers.

Unresolved Tension Between Oversight and Access

The enrollment freeze creates unresolved policy tension: federal law technically requires enhanced hospice oversight, yet the administration has suspended the systematic identification program and now frozen new provider enrollment. This combination effectively consolidates the existing provider network while eliminating systematic quality identification mechanisms. Medicare Advocacy organizations have called for expeditious implementation of revised oversight methodology, warning that the current approach leaves beneficiaries vulnerable to fraud and quality deficiencies while preventing qualified new providers from serving unmet demand.

The freeze ultimately reflects competing priorities: industry demands for regulatory relief, beneficiary needs for access and quality assurance, and federal obligations for program integrity. Whether this approach represents temporary regulatory recalibration or permanent policy reorientation remains unclear as the administration provides no timeline for enrollment reopening or revised oversight implementation.